Extraordinary General Meeting of Kinarus Holding approved all resolutions
relating to the envisaged Business Combination with Curatis

Kinarus Therapeutics Holding AG / Key word(s): AGMEGM
Extraordinary General Meeting of Kinarus Holding approved all resolutions
relating to the envisaged Business Combination with Curatis

01.03.2024 / 18:36 CET/CEST

---------------------------------------------------------------------------

MEDIA RELEASE

Basel, Switzerland, 1 March 2024: Kinarus Therapeutics Holding AG (SIX:KNRS)
('Kinarus Holding', 'KNRS' or the 'Company'), a SIX Swiss Exchange listed
therapeutic drug development company announced today that at the
Extraordinary General Meeting of Kinarus Holding held on Friday, 1 March
2024, the shareholders of Kinarus Holding have approved with sweeping
majorities all resolutions relating to the envisaged Business Combination
with Curatis AG, a Basel-Landschaft incorporated medicine distribution and
drug development company predominantly focused on orphan/ultra-orphan
diseases and specialty care diseases ('Curatis').

Closing of the Transaction is expected to occur at the end of April 2024. In
addition to Kinarus Holding shareholder approval, completion of the proposed
Business Combination is subject to satisfaction of certain other conditions.

About Kinarus Therapeutics Holding AG

Kinarus AG in Liquidation (www.kinarus.com) was founded in 2017 by
experienced pharmaceutical executives in Basel, Switzerland. The Kinarus
Group consists of the SIX Swiss Exchange listed Kinarus Therapeutics Holding
AG and the operating fully owned subsidiary Kinarus AG in Liquidation. Both
Kinarus Therapeutics Holding AG and Kinarus AG in Liquidation have filed for
bankruptcy in September 2023 after a financing agreement with a Chinese
investment company in May 2023 has not led to the agreed payments. Kinarus
AG in Liquidation possesses the exclusive worldwide license to pamapimod,
covering all indications, and has patented KIN001, its novel mechanism in
combination with pioglitazone.

For more information, please visit the company's website at www.kinarus.com.

Investor Relations Contact:

YUMA Capital
Thomas Bieri
Managing Partner
Tel: +41 44 575 20 01
thomas.bieri@yuma-capital.com

Disclaimer

THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS WITHIN THE MEANING OF SWISS
FINANCIAL SERVICES ACT ('FINSA'), NOR A PROSPECTUS UNDER ANY OTHER
APPLICABLE LAWS AND SHOULD NOT BE TREATED AS OFFERING MATERIALS OF ANY SORT
AND IS FOR INFORMATION PURPOSES ONLY. THE INFORMATION CONTAINED HEREIN IS IN
SUMMARY FORM AND MUST BE CONSIDERED IN CONJUCTION WITH AND SUBJECT TO THE
PUBLICLY AVAILABLE INFORMATION OF KINARUS THERAPEUTICS HOLDING AG. THIS
DOCUMENT IS BEING FURNISHED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT
BE REPRODUCED, REDISTRIBUTED OR MADE AVAILABLE IN WHOLE OR IN PART TO ANY
OTHER PERSON OR ANY PURPOSE, WITHOUT THE PRIOR WRITTEN CONSENT OF KINARUS
THERAPEUTICS HOLDING.

This document contains certain forward-looking statements. Other written
materials, as well as other written and oral statements made to the public,
may also contain forward-looking statements. Forward-looking statements can
be identified by words such as 'potential,' 'expected,' 'will,' 'planned,'
'pipeline,' 'outlook,' 'may,' 'could,' 'would,' 'anticipate,' 'seek,' or
similar terms, or by express or implied discussions regarding potential new
products, potential new indications for existing products, or regarding
potential future revenues from any such products; or regarding the potential
outcome, or financial or other impact on Kinarus Therapeutics Holding AG, of
any of the transactions described; or regarding potential future sales or
earnings of the group or any of its divisions or potential shareholder
returns; or by discussions of strategy, plans, expectations or intentions.
Such forward-looking statements are based on the current beliefs and
expectations of management regarding future events, and are subject to
significant known and unknown risks and uncertainties. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those set forth in
the forward-looking statements. You should not place undue reliance on these
statements.

This document is not an offering circular or prospectus and is being
furnished to you solely for your information and may not be reproduced,
redistributed or made available in whole or in part to any other person for
any purpose, without the prior consent of Kinarus Therapeutics Holding AG.
This document is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgement. It is not
intended as investment advice and under no circumstances is it to be used or
considered as an offer to sell, or a solicitation of an offer to buy, any
security nor is it a recommendation to buy or sell any security. Any
decision to subscribe to any securities should only be made on the basis of
an independent review by you of Kinarus Therapeutics Holding AG publicly
available information. Kinarus Therapeutics Holding AG does not accept any
liability arising from the use of, or make any representation as to the
accuracy or completeness of, this document or the publicly available
information on Kinarus Therapeutics Holding AG. We provide the information
in this document as of the date hereof and the information contained in this
document is subject to change at any time. We do not intend, and do not
assume any obligation, to update any information or forward-looking
statements set out in this document as a result of new information, future
events or otherwise. Kinarus Therapeutics Holding AG shall not be
responsible for, or for investigating, any matter which is the subject of
any statement, representation, warranty or covenant of Kinarus Therapeutics
Holding AG contained in any other agreement or document relating to a
transaction (including the contemplated Combination Transaction with Curatis
AG announced with a media release on 29 January 2024, the 'Transaction'), or
for the execution, legality, effectiveness, adequacy, genuineness, validity,
enforceability or admissibility in evidence thereof. This document is not
for distribution, directly or indirectly in or into the United States (as
defined in Regulation S under the US Securities Act of 1933, as amended ('US
Securities Act')). This document is not an offer to sell securities, or the
solicitation of any offer to buy securities, nor shall there be any offer of
securities in any jurisdiction in which such offer or sale would be
unlawful. The securities mentioned in this document have not been and will
not be registered under the US Securities Act, and may not be offered or
sold in the United States absent registration or exemption from registration
under the US Securities Act. There will be no public offer of the securities
in the United States or in any other jurisdiction. The securities in
connection with this Transaction may not be offered to the public in any
jurisdiction in circumstances which would require Curatis AG or Kinarus
Therapeutics Holding AG to prepare or register any prospectus or offering
document relating to the securities in connection with the Transaction in
such jurisdiction.


---------------------------------------------------------------------------

End of Media Release

---------------------------------------------------------------------------

1849923 01.03.2024 CET/CEST